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Background: In castration-resistant prostate cancer (CRPC), recent evidence has demonstrated the persistence
of the intratumoral androgens. The multi-step androgen synthesis pathway originates from cholesterol, which
can be obtained by cells from several major sources including intracellular synthesis through an enzyme 3-hydroxy-
3-methylglutaryl-coenzyme A reductase (HMGCR). The inhibition of this enzyme by the use of statins has been
investigated in prostate cancer as a possible therapeutic target for blocking the de novo androgen synthesis
resulting in decreased tumor growth. However, the effectiveness of statins in CRPC has not been investigated.
Methods: Castration-resistant C4-2 and androgen-sensitive LNCaP cells were treated with Simvastatin for 48 hours.
Dose-dependent responses to Simvastatin were analyzed using cell proliferation and cytotoxicity assays. Cellular
growth curve was generated using haemocytometer. HMGCR activity was assessed using 14C-acetic acid detected
by thin layer chromatography, and the protein expression was quantified using western blot analysis. Intracellular
cholesterol and prostate specific antigen (PSA) levels were quantified using enzyme-linked immunosorbent assays
(ELISA).
Results: Significant decrease in cell viability and growth curve observed at 75 μM of Simvastatin compared to no
treatment group in the castration-resistant C4-2 cells. HMGCR activity was significantly decreased up to 50% and
70% at 50 μM and 75 μM of Simvastatin respectively compared to the vehicle control in C4-2 cells. Simvastatin did
not affect the protein expression. 80% decrease in the amount of total intracellular cholesterol levels was observed
in 75 μM Simvastatin treatment group compared to vehicle control. PSA secretion levels were significantly reduced
in the C4-2 cell line at 50 μM and 75 μM of Simvastatin compared to vehicle control.
Conclusion: The inhibition of HMGCR via Simvastatin lowered the viability of castration-resistant C4-2 cells.
Simvastatin’s ability to limit the endogenous supply of cholesterol contributes to the effects seen in cell viability.
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Prostate cancer (PCa) occurs in the form of an unregu-
lated cellular growth in the prostate, a gland in the male
reproductive system, leading to symptoms such as erect-
ile dysfunction, hematuria, and pain. PCa is commonly
diagnosed in men over the age of 50, after which inci-
dence rates increase with age; it is the most common
cancer diagnosed among North American men, account-
ing for 28% of all cancers diagnosed, and is the second
most common cause of cancer death among the same
cohort (10%) in 2012 [1,2]. Upon diagnosis, local PCa is* Correspondence: kwasan@mail.ubc.ca
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unless otherwise stated.treated with surgical removal of the tumor, radiation
therapy, and/or androgen deprivation therapy (ADT).
Within the prostate gland, androgens such as testoster-
one and dihydrotestosterone (DHT) promote cell growth
and proliferation via androgen receptor (AR), a ligand-
responsive transcription factor. Upon ADT, 99% of
prostate cancer patients reach 5-year survival due to
apoptotic regression of tumor from the lack of androgen
growth stimuli [3,4]. However, patients with metastatic
prostate cancer are subject to temporary remission.
Eventually the tumor regrows despite the depleted level
of circulating androgens that is insufficient to support
the prostate tumor growth; this is referred to as
castration-resistant prostate cancer (CRPC) [3,4].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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independent’ cancer due to its ability to grow and
metastasize despite the low androgen environment. Re-
cent findings by multiple groups however have shown
that CRPC cells have the ability to produce their own
intracellular androgens that promote growth via AR acti-
vation without having to rely on exogenous androgen
supply – known as intratumoral de novo steroidogenesis
[5,6]. Androgen levels within metastastic tumors of cas-
trated men are found to be higher than the levels within
the primary prostate cancer tumors in untreated men
[7]. In addition, CRPC tumors are shown to continu-
ously express the necessary enzymes to create androgens
intracellularly [8,9]. While the steps towards androgen
production consist of multiple pathways, all the steps
originate from a common upstream precursor molecule,
cholesterol [10].
Cellular cholesterol homeostasis is comprised of com-
plex and multiple regulatory pathways as cholesterol has
important functions in humans including regulating
membrane fluidity, influencing cellular signaling, and
being a precursor for bile and androgens [11]. Cells ob-
tain cholesterol from two major sources: exogenous and
endogenous supplies. Exogenous cholesterol supply in-
volves uptake of cholesterol from circulating lipoproteins
via membrane transporters such as Scavenger Receptor
Class B Type I (SR-BI) and low density lipoprotein re-
ceptor (LDLr). Once in the cell, cholesterol is stored as
cholesteryl esters in lipid droplets and metabolized ac-
cordingly to cell’s demand for cholesterol via acetyl-CoA
acyltransferase (ACAT) and hormone sensitive lipase
(HSL). Endogenously, cholesterol is synthesized from
acetyl-CoA in the endoplasmic reticulum through is
the mevalonate pathway, in which the rate-limiting is
step 3-hydroxy-3-methylglutaryl-coenzyme A reductase
(HMGCR) that is responsible for converting 3-hydroxy-
3-methylglutaryl-coenzyme A (HMG-CoA) into mevalo-
nate [11,12]. Mevalonate molecule further undergoes
multiple reactions to be converted into cholesterol
downstream.
While normal physiological cholesterol homeostasis is
tightly regulated, it has been shown that this process is
dysregulated in CRPC, suggesting a constant, unregu-
lated supply of cholesterol to meet cellular requirements
including supply for de novo steroidogenesis [6,13,14]. A
potential site of dysregulation has shown to be at site of
cholesterol uptake via SR-BI; our group has shown that
SR-BI protein expression was significantly increased
upon progression to castration-resistance in the LNCaP
xenograft model [8]. Also, upon inhibition of cholesterol
uptake via SR-BI silencing in vitro, a compensatory chol-
esterol synthesis via increased HMGCR activity was
identified and significant decreases in prostate specific
antigen (PSA) and cell viability of CaP cells wereobserved [15]. However, relevant changes in total choles-
terol concentration and androgen levels were not seen,
most likely due to the activation of compensatory chol-
esterol synthesis via HMGCR [15]. Recently, our group
has demonstrated that HMGCR expression and activity,
and thereby cholesterol synthesis, was increased during
CRPC progression in LNCaP xenografts [6,16]. Statins,
inhibitors of HMGCR, have been the subject of many
PCa studies with mixed results [17-19]. Recently, an
association between statin users and a reduction in the
onset of the aggressive, late-stage disease state was re-
ported and has been paired with decreased serum andro-
gens [20]. However to date, only a handful of research
has looked directly at the effect of statin as a treatment
option for CRPC; it has been shown that inhibition of
cholesterol synthesis via statin prevents cell proliferation
by inducing apoptosis through reduction in nuclear
factor-κB activity [21]. However there are limitations to
the studies with regards to cell line specificity, and the
lack of cholesterol metabolism data.
The present study sought to determine the role of
HMGCR in castration-resistant prostate cancer cells in
terms of cell viability, cholesterol synthesis, and PSA
production when the cholesterol synthesis via HMGCR
is blocked with Simvastatin. LNCaP and C4-2 cells share
similar features by expressing AR and producing PSA;
C4-2 cells are lineage-derived second generation subline
of LNCaP cells that were derived by subcutaneous co-
inoculation of LNCaP and osteosarcoma cells in cas-
trated mice [22]. Therefore, LNCaP cells were selected
as the appropriate control cell line.
Results
C4-2: castration-resistant prostate cancer cell line
Cytotoxicity of simvastatin treated C4-2 cells
The cytotoxicity of cells was measured based on the
presence of lactate dehydrogenase (LDH) in the media,
which indicates poor cellular membrane integrity and
cell lysis. LDH in media causes the conversion of a tetra-
zolium salt reagent into a red formazan product, which
the absorbance can be measured at 492 nm. Results are
expressed as values normalized to a 100% death control
which represents untreated cells lysed with a 1% Triton
X-100 solution. The means of the cytotoxicity measured
at different Simvastatin doses were compared to the
Vehicle Control, consisting of 0.5% DMSO. The means
were found to be significantly different at 60 μM,
75 μM, 80 μM, 100 μM, and 250 μM in C4-2 cells
(Figure 1).
Cell viability and growth curve of simvastatin treated
C4-2 cells
The cell viability was measured based on the presence is
of dehydrogenase enzymes in metabolically active cells
Figure 1 Cell cytotoxicity is demonstrated as % cytotoxicity based on a 100% cytotoxic control, representing the amount of LDH in
the media of C4-2 cells treated with increasing dose of Simvastatin. Columns, mean (n = 5); bars, ±SEM. *P < 0.05, Vehicle control versus μM,
80 μM, 100 μM, 250 μM.
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2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) tetrazolium reagent into a colored
formazan product that can be measured at 490 nm, pro-
ducing signal measurements that are directly propor-
tional to the number of living cells in culture. The
viability of cells was normalized to protein levels (μg) in
the respective cell samples. As shown in Figure 2, cellu-
lar viability, expressed as fold change from negative con-
trol, decreased significantly at 75 μM, 80 μM, 100 μM,
250 μM, and Triton-X 1% control for C4-2 cells in a
dose-dependent manner.
The cumulative growth curve was generated to ob-
serve the long-term cell growth patterns over 8 days
post-seeding by measuring the total cell count using
haemocytometer at 48 hours post-seeding (Day 2), be-
fore SV treatment on Day 3, 48 hours post-treatmentFigure 2 Cell viability is demonstrated as fold change in viability from
of Simvastatin. Columns, mean (n = 5); bars, ±SEM. *P < 0.05, Vehicle cont(Day 5), and 72 hours post-Simvastatin removal (Day 8).
As shown in Figure 3, the only significant difference in
the growth pattern of C4-2 cells upon Simvastatin treat-
ments compared to vehicle control was at 75 μM of
Simvastatin at Day 8. Despite the difference in the
growth rate of C4-2 cells at 75 μM compared to vehicle
control at Day 5, the difference was not statistically
significant.
HMGCR activity and protein expression
β-scintillation readings of silica gel at a Rf value of ap-
proximately 0.25 indicated the location of cholesterol on
the stationary phase as compared to positive cold chol-
esterol control sample. The measurements were used to
assess the cholesterol synthesis activity via HMGCR en-
zyme by the incorporation of radiolabeled acetate pre-
cursor molecule into cholesterol synthesis pathway. Thethe negative control in C4-2 cells treated with increasing dose
rol versus 60 μM, 75 μM, 80 μM, 100 μM, 250 μM and TX1%.
Figure 3 Cumulative cell growth curve expressed as total cell count of C4-2 cells over 8 days. Curve, mean (n = 5); error bars, ± SEM.
*P < 0.05, Vehicle control versus TX1% in C4-2 at Day 5; Vehicle control versus 75 μM and TX1% at Day 8.
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malized to protein levels (μg) as measured by Lowry
assay. The mean cholesterol synthesis activities in C4-2
cells significantly decreased up to 50% and 70% upon
50 μM and 75 μM of Simvastatin respectively compared
to vehicle control group (Figure 4).
Western blot analysis of C4-2 cell lysates showed that
there is no significant decrease in HMGCR expression
upon Simvastatin treatments when compared to the ve-
hicle control (Figure 5).
Cellular cholesterol of simvastatin treated C4-2 cells
The total intracellular cholesterol concentrations were
measured in C4-2 cells treated with Simvastatin for
48 hours, and the values were normalized to proteinFigure 4 Cholesterol synthesis measurement by incorporation of 14C-
counter in C4-2 after 48 hour Simvastatin treatment followed by 3 ho
chromatography. Columns, mean (n = 5); bars, ±SEM. *P < 0.05, Vehicle Co(mg) in the cell samples from the respective wells of
whole cell lysates. Significant decrease in the amount of
total cholesterol was observed at 75 μM of Simvastatin
compared to vehicle control in C4-2 cells (Figure 6).
The decrease in cholesterol levels corresponded to the
decrease in HMGCR protein activity at 75 μM Simva-
statin treatment results.
PSA secretion is reduced in C4-2 cells treated with
simvastatin
The levels of PSA secretion of C4-2 cells were quantified
in the supernatant or treated cells. The amount of PSA
is expressed as concentration (ng/mL) and was then
normalized to the amount of protein (mg) in the cell
samples from the respective wells of the analyzedacetic acid into cellular cholesterol as measured by β-scintillation
ur 14C-acetic acid treatment and separation by thin layer
ntrol versus 50 μM, and 75 μM.
Figure 5 Relative protein expression in C4-2 cells to vehicle control expression after 48 hour Simvastatin treatment, normalized to
actin expression. Columns, mean (n = 4); bars, ±SEM.
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less at 50 μM and 75 μM of Simvastatin treatments
compared to vehicle control in C4-2 cells; vehicle con-
trol had secreted 192.1 ± 52.0 ηg/mL per mg protein as
compared to 34.4 ± 15.4 ng/mL per mg at 50 μM and
41.32 ± 14.0 ng/mL per mg at 75 μM of Simvastatin
treatments (Figure 7).
LNCaP: androgen-sensitive prostate cancer cell line
Cytotoxicity results expressed as mean values normal-
ized to a 100% death control were found to be signifi-
cantly different at 60 μM, 75 μM, 80 μM, 100 μM, and
250 μM when compared to vehicle control group’s
cytotoxicity mean value (Figure 8). Corresponding cell
viability results were observed where cellular viability,
expressed as fold change from negative control, de-
creased significantly at 75 μM, 80 μM, 100 μM, and
250 μM, and Triton-X 1% control (Figure 9). TheFigure 6 Total cholesterol concentration in whole cell lysates of C4-2
bars, ±SEM. *P < 0.05, Vehicle control versus 75 μM.control LNCaP cells showed a cumulative growth curve
that was showed a significant difference in the growth
pattern of upon 75 μM of Simvastatin treatment com-
pared to vehicle control at Days 5 and 8 (Figure 10).
Upon Simvastatin treatments, LNCaP cells displayed a
significant reduction in cholesterol synthesis activity is at
75 μM of Simvastatin treatment as shown in Figure 11;
however, no significant changes were observed in
the HMGCR expression across the Simvastatin doses
(Figure 12). The total intracellular cholesterol concen-
trations, normalized to protein levels (mg), showed
a significant reduction in the total cholesterol concen-
tration at 75 μM of Simvastatin compared to vehicle
control (Figure 13). The decrease in cholesterol levels
corresponded to the decrease in HMGCR protein
activity at 75 μM Simvastatin treatment results. Despite
the change in cholesterol synthesis activity and total
intracellular cholesterol concentration, there were nocells after 48 hour Simvastatin treatment. Columns, mean (n = 6);
Figure 7 PSA production demonstrated as secreted PSA levels in the media of C4-2 after 48 hour Simvastatin treatment. Columns,
mean (n = 6); bars, ±SEM. *P < 0.05, Vehicle control versus 50 μM and 75 μM.
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secretion (ng/mL) of LNCaP cells, normalized to the
amount of protein (mg), upon Simvastatin treatments
(Figure 14).
Discussion
In the past castration-resistant prostate cancer, now with
a median overall survival of 18.4 months with combin-
ation therapy of docetaxel and AR blocker MDV3100,
was misunderstood as an ‘androgen independent’ form
of prostate cancer based on the observations that it is able
to recur and more importantly aggressively metastasize in
patients treated with androgen deprivation therapy [23].
As mentioned however, many groups have reported theFigure 8 Cell cytotoxicity is demonstrated as % cytotoxicity based on
the media of LNCaP cells treated with increasing dose of Simvastatin
75 μM, 80 μM, 100 μM, 250 μM and TX1%.continuous expression of AR and activation of the AR-
androgen signaling pathway in castration-resistant pros-
tate cancer through both in vitro as well as in vivo studies
despite the androgen castrated environment, supporting
the existence of an intracellular de novo androgen synthe-
sis pathway rather than the tumor’s ability to sustain itself
despite the lack of androgens [24-27].
HMGCR has been shown to be essential regulator for
provision of cholesterol to the androgen synthesis path-
way in the steroidogenic tissues of the body [15]. Upon
progression to castration-resistance in LNCaP xenograft
model, an increase ex vivo HMGCR activity has been
observed [6]. Also, in castration resistant cell model
upon the knockdown of SR-BI transporter a significanta100 % cytotoxic control, representing the amount of LDH in
. Columns, mean (n = 5); bars, ±SEM. *P < 0.05, Vehicle control versus
Figure 9 Cell viability is demonstrated as fold change in viability from the negative control in LNCaP cells treated with increasing dose
of Simvastatin. Columns, mean (n = 5); bars, ±SEM. *P < 0.05, Vehicle control versus 60 μM, 75 μM, 80 μM, 100 μM, 250 μM and TX1%.
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finding suggests that castration-resistant cells may
adapt to the low androgen environment by increasing
cholesterol synthesis to supply cellular needs as well
as providing the precursor for de novo androgen
synthesis. While suggesting an important role of this
enzyme in intracellular de novo androgen synthesis
and potentially suggesting common HMGCR inhibi-
tors such as statins as possible therapeutic agent, the
effect of inhibiting HMGCR in a castration-resistant
model has not been investigated. The current study
aimed to investigate the physiological relevance of
one source of cholesterol to the cell, HMGCR, a
rate-limiting enzyme in the cholesterol synthesis-
mevalonate pathway.Figure 10 Cumulative cell growth curve expressed as total cell count
*P < 0.05, Vehicle control versus 75 μM and TX1% in at Day 5 and 8.Simvastatin is a commonly used drug to control hyper-
cholesterolemia to prevent cardiovascular disease, and as
such epidemiological studies have shown significantly
lower serum PSA, tumor volume, and percentage of
cancer in radical prostatectomy samples in PCa patients
on preoperative statins compared to non-users [28,29].
As mentioned, the effects of statins in prostate cancer
models have been extensively studied in cell and animal
models as well, reporting a decrease in tumor viability
and proliferation in PC-3 in vitro model as well as re-
duction in PSA production in mice in vivo model; how-
ever, the effects have not been thoroughly investigated in
CRPC models [24-27]. The treatment of Simvastatin in
androgen-sensitive LNCaP cells confirmed the cytotoxic
effects as seen in previous studies (Figure 1). In addition,of LNCaP cells over 8 days. Curve, mean (n = 5); error bars, ± SEM.
Figure 11 Cholesterol synthesis measurement by incorporation of 14C-acetic acid into cellular cholesterol as measured by β-scintillation
counter in LNCaP after 48 hour Simvastatin treatment followed by 3 hour 14C-acetic acid treatment and separation by thin layer
chromatography. Columns, mean (n = 5); bars, ±SEM. *P < 0.05, Vehicle control versus 75 μM.
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cantly stunted the cellular growth of castration-resistant
C4-2 cells in a similar dose-dependent manner as the
control LNCaP cells (Figures 1 and 8). The two cell lines
were shown to display cellular cytotoxicity, viability, and
growth curve patterns that are not significantly different
from each other; both cell lines showed nearly 50%
reduction in cell viability after 48 hour incubation of
75 μM of Simvastatin (Figures 1, 2 and 3).
Cholesterol is an important precursor molecule in the
pathways involved in the production of androgens,
which stimulate prostate growth; the changes in growth
and proliferation seen in Figures 1, 2 and 3 may be a re-
sult of cholesterol synthesis alteration caused by Simva-
statin. Upon Simvastatin treatments, C4-2 cells showed
significant changes in the HMGCR activity, normalizedFigure 12 Relative protein expression in LNCaP cells to vehicle contro
actin expression. Columns, mean (n = 4); bars, ±SEM.to protein amount (μg), at 50 μM and 75 μM of Simva-
statin (Figure 4). Corresponding to past studies which
reported an increase in ex vivo HMGCR activity upon
progression to castration-resistance in a LNCaP xeno-
graft model, the current study also reported a five-fold
increase in basal cholesterol synthesis activity in the no
treatment groups of C4-2 cells compared to LNCaP cells
as shown in Figures 4 and 11 [6]. Upon examining the
HMGCR protein expression levels, Simvastatin treat-
ment did not significantly alter the expression of the
HMGCR protein in C4-2 and LNCaP cells (Figures 5
and 12); as a competitive inhibitor of HMGCR, statins
are not known to affect the enzyme function via silen-
cing mechanism. Corresponding to the HMGCR activity
results, at 75 μM of Simvastatin both cell lines showed
a significant decrease in the intracellular cholesteroll expression after 48 hour Simvastatin treatment, normalized to
Figure 13 Total cholesterol concentration in whole cell lysates of LNCaP cells after 48 hour Simvastatin treatment. Columns, mean
(n = 6); bars, ±SEM. *P < 0.05, Vehicle control versus 75 μM.
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and 13). However in C4-2 cells, upon 50 μM of Simva-
statin, the intracellular cholesterol quantity remained the
same despite the decrease in HMGCR activity, which
may be an indication of compensatory pathways activa-
tion to supply the cell with the necessary cholesterol
source via other cholesterol homeostasis pathways des-
pite the inhibition of HMGCR (Figures 4 and 6).
An important indication of AR-androgen pathway acti-
vation is the production of PSA, which is produced in re-
sponse to transcription of genes that contain androgen
response elements (AREs). Similar to the PSA observa-
tions seen in previously published papers, the basal PSA
secretion levels in C4-2 cells was significantly higher; the
current study showed an increase that is approximately
five magnitude greater in C4-2 cells than the amount se-
creted by LNCaP cells (Figures 7 and 14) [30]. WhileFigure 14 PSA production demonstrated as secreted PSA levels in the
Columns, mean (n = 6); bars, ±SEM.previous studies have reported a lack of change in the level
of AR protein expression between LNCaP and C4-2 cells,
statin use has been shown to decrease the expression and
activity of the AR via suppression of the Akt/mTOR sig-
naling pathway [15,30] These finding indicates the exist-
ence of a continuous androgen supply, and whether there
is a greater total amount of androgens to activate the AR
or the ligand-receptor binding interaction is stronger in
C4-2 cells is unknown. Furthermore, the inhibition of
cholesterol synthesis significantly reduced the secreted
PSA levels in C4-2 cells at 50 μM and 75 μM of Simva-
statin compared to vehicle control, while no differences
were observed in LNCaP cells across the treatment groups
implicating that the decrease in cholesterol synthesis has a
greater effect in castration-resistant state and supporting
the hypothesis of existence and greater reliance on intra-
cellular de novo steroidogenesis in CRPC.media of LNCaP after 48 hour Simvastatin treatment.
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Simvastatin like most other statins may exert choles-
terol-independent or pleiotropic effects through direct
inhibition of small signaling molecules; by inhibiting
HMGCR, statins inhibit cholesterol synthesis as well as
the synthesis of isoprenoids which are important lipid
attachments for intracellular signaling molecules such as
Rho, Rac, and Cdc42 [31,32]. Despite the decreases in
HMGCR activity, total intracellular cholesterol, and
PSA, if a constant intracellular testosterone level across
the Simvastatin treatment groups were observed, it may
indicate that the signaling processes are being affected.
In the current study, the decrease in PSA secretion may
be due to the direct effect of Simvastatin on cholesterol-
androgen production and androgen receptor activation
and/or indirect effect on the signaling pathways.
The effect of regulating the cholesterol homeostasis
pathway to alter the growth of CRPC cells has also been
seen in cholesterol influx regulation [15]. Recently
scavenger-receptor class B type I (SR-BI) receptor has
also emerged as a potential therapeutic target of interest
in investigating PCa progression as well as de novo an-
drogen synthesis due to the discovery of a significant in-
crease in the SR-BI protein expression in CRPC cells
compared to non-castrated LNCaP cells [15]. SR-BI re-
ceptor is one of the two major cholesterol influx trans-
porters, mainly uptake of cholesterol esters bound to
high density lipoprotein (HDL) via a docking mechan-
ism. It has been shown that down-regulation of SR-BI
expression via gene silencing significantly reduced the
viability of C4-2 cells, and at a greater extent compared
to LNCaP cells [15]. Furthermore, a significant reduction
in the amount of PSA secreted by both C4-2 and LNCaP
cells was observed when comparing SR-BI knockdown
to negative control cells [15]. However, the limitations of
the study were that no corresponding differences in
intracellular cholesterol and androgen levels were ob-
served. The results from the current study looking at in-
hibition of cholesterol synthesis via use of Simvastatin
reported a significant reduction in cell viability, intracellu-
lar cholesterol levels, PSA secretion, and cholesterol syn-
thesis activity in C4-2 cells upon Simvastatin treatments.
It would be worthwhile to investigate the inhibition of
multiple cholesterol regulatory pathways including choles-
terol influx and synthesis using combination treatment of
SR-BI silencing and Simvastatin to assess the effect of a
combination treatment in CRPC models.
Conclusion
In summary, the inhibition of HMGCR via Simvastatin
lowered the viability of castration-resistant C4-2 cells.
Simvastatin’s ability to limit the endogenous supply of
cholesterol likely contributes to the effects seen in cell
viability.Materials and methods
Materials
Poly-L-lysine (0.01% solution), cholesterol, Triton® X-100,
dimethyl sulphoxide, phenylmethylsulfonyl fluoride, prote-
ase inhibitor cocktail, Trizma®-hydrochloride, Trizma®
base, glycine, lyophilized bovine serum albumin, sodium
dodecyl sulfate, ammonium persulfate, tetramethylethyle-
nediamine, sodium hydroxide, sodium chloride, sodium
deoxycholate, nonyl phenoxypolyethenyl ethanol (NP-40)
and ethylenediamininetetraacetic acid (Sigma-Aldrich, St.
Louis, MO, USA), acetic acid [1-14C]- (American Radiola-
beled Chemicals, Inc., Saint Louis, MO, USA), cholesterol
[1, 2-3H(N)]- (PerkinElmer Inc. Waltham, MA, USA).
Scintillation fluid was purchased from MP Biomedicals
(Solon OH, USA). RPMI-1640 without phenol red, Hank’s
balanced salt solution, 0.25% trypsin-EDTA, penicillin-
streptomycin liquid, fetal bovine serum, charcoal-stripped
fetal bovine serum, were purchased from Invitrogen
(Life Technologies, Invitrogen, Burlington, Ontario).
Chloroform, ethyl acetate, hexanes, ethanol, methanol
and isopropanol were purchased from Fisher Scientific
(Waltham, MA, USA). SuperSubstrate® West Pico Solu-
tion was obtained from Thermo Scientific (Rockford IL,
USA).Cell culture
C4-2 and LNCaP cells were obtained from the Vancouver
Prostate Centre. LNCaP cells were used for experiment
between the passage numbers of 42-52. The cells were
cultured in RPMI-1640 medium without phenol red
containing 10% fetal bovine serum and 1% penicillin-
streptomycin at 37°C in 5% CO2 environment. 72 hours
prior to Simvastatin treatment, the cells were seeded in
plates in 10% fetal bovine serum supplemented RPMI
medium. After the initial 24 hours, the medium was
replaced with RPMI medium supplemented with 5%
dextran-charcoal stripped medium with restricted andro-
gens to mimic an androgen-castrated environment. Cells
were seeded in plates to include vehicle control, Simva-
statin treatment, no treatment (NT) and 100% cell lysis
(Triton X100, 1%) control wells.Cell cytotoxicity and viability
Cells were plated in 96-well plates at a density of 6 × 103
cells per well 72 hours prior to Simvastatin treatment.
Treatments and controls were assigned in triplicates in
each plate. 50 μL of media was taken from above the
cells 48 hours post Simvastatin incubation for LDH
cytotoxicity assay. The remaining cells were rinsed with
Hank’s Balanced Salt Solution (HBSS) and MTS assay
was performed to detect cell viability. Protein determin-
ation was performed using BSA assay to normalize the
MTS values to protein concentration.
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Cells were plated in 6-well plates at a density of 1.8 × 105
cells per well 72 hours prior to Simvastatin treatment.
48 hour post-seeding (Day 0), cells were carefully detached
from the plates using 0.25% Trypsin-EDTA, and counted
using haemocytometer. The procedure was repeated at
72 hour post-seeding (Day 1), 48 hours post-Simvastatin
treatment (Day 3), and 72 hours post-Simvastatin treat-
ment removal (Day 6).
Cholesterol synthesis (HMGCR activity) assay
C4-2 and LNCaP cells were seeded in 12-well plates at a
density of 8 × 105 cells per well 72 hours prior to Simva-
statin treatment. Following the Simvastatin treatment
for 48 hours, the cells were washed twice with HBSS
and labeled with 0.5 μCi of 14C-acetic acid prepared in
fresh Simvastatin solutions for 3 hours. Cells were
washed three times with HBSS following incubation.
The lipid content in the samples was extracted using the
Bligh Dyer lipid extraction method as previously de-
scribed, dried under nitrogen, and reconstituted in
chloroform [33]. The chloroform samples were sepa-
rated using thin layer chromatography on silica gel plate
in 9:1 hexane to ethyl acetate solution. A 10 mg/mL cold
cholesterol sample and an internal extraction control,
3H [1,2]-cholesterol loaded at 1 uCi/mL, were included
in the thin layer chromatography procedure as controls.
After the solution has reached the top, the plate was air-
dried and exposed to iodine crystals. The yellow choles-
terol bands were excised and reconstituted in scintilla-
tion counter fluid to be measured in beta scintillation
counter (Perkin Elmer).
Protein expression
Protein levels were measured in the collected supernatants
and known amounts of protein were separated using
4-15% SDS gels. Protein transfer, membranes were
blocked and incubated overnight with HMGCR (Upstate
Biotech®) and β-actin (Santa Cruz®) 1° antibodies at 1:1000
dilutions. Membranes were then incubated with HRP-
labeled 2° antibodies at a 1:3000 dilution to detect the pro-
teins using chemiluminescence detection method.
Quantification of cholesterol and prostate specific antigen
The Amplex Red Cholesterol assay (Invitrogen) was per-
formed as per manufacturer’s instructions to measure
the total intracellular cholesterol amount. 50 μL of cell
extracts and cholesterol reference standards were ali-
quoted in triplicates into a 96-well plate and Amplex
Red reaction buffer and working solution were added.
Plates were incubated for thirty minutes at 37°C in the
dark. Fluorescence was measured using an excitation
wavelength of 560 nm and an emission wavelength of590 nm. Cholesterol concentration was normalized to
the amount of protein present in the lysates.
The amount of PSA secreted by the cancer cells was
quantified using the PSA ELISA assay (ProClin Inter-
national). 50uL of reference standards and media from
each treatment and control wells were aliquoted in trip-
licates into a 96-well plate. Following incubations with
reaction buffer, enzyme conjugate reagent, and TMB re-
agent, the optical density was measured at 450 nm and
the PSA concentration was normalized to the amount of
protein present in the media.
Statistical analysis
All data are presented as mean + standard error of the
mean. Paired t-tests and one-way ANOVA tests (Sigma-
Stat 3.5) were performed to compare the normalized ex-
pressions and concentrations between treatment groups.
Tukey post hoc tests were done to determine the critical
differences, and a difference was considered to be signifi-
cant if the probability of chance explaining the difference
was less than 5% (p < 0.05).
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